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*Serratia marcescens*, first described in 1819, belongs to the family of *Enterobacteriaceae* and is a motile rod-shaped Gram-negative bacterium ([@B1]). *Serratia* species are omnipresent in the environment, and *S. marcescens* is classified as an important nosocomial pathogen causing a wide range of infections, including, most notably, urinary tract infection and bloodstream infection ([@B2]). Besides several potential virulence factors, one important feature of clinical *S. marcescens* is its ability to acquire antimicrobial resistance. VIM-metallo-β-lactamase (MBL)-producing isolates have the ability to hydrolyze almost all β-lactams and have been described in association with outbreaks worldwide ([@B3]).

In 2017, in Austria, *S. marcescens* strain at10508 was cultured from a 68-year-old male patient with clinical signs of chronic obstructive pulmonary disease (COPD), pneumonia, brain abscess due to a *Nocardia* sp., diabetes mellitus type 2, liver cirrhosis, coronary heart disease, ascites, and pleural effusion. Antimicrobial resistance was determined using BD Phoenix (Becton Dickinson, Franklin Lakes, NJ, USA), yielding the following results: ampicillin (resistant \[R\]), ampicillin-sulbactam (R), amoxicillin-clavulanic acid (R), piperacillin (R), piperacillin-tazobactam (R), cefazolin (R), cefepime (R), cefotaxime (R), ceftazidime (R), cefuroxime (R), ertapenem (R), imipenem (R), meropenem (R), ciprofloxacin (R), levofloxacin (R), amikacin (sensitive \[S\]), gentamicin (S), tobramycin (R), tetracycline (R), tigecycline (intermediate \[I\]), colistin (R), fosfomycin (R), and trimethoprim-sulfamethoxazole (R).

For whole-genome sequencing, high-molecular-weight DNA was isolated from an overnight culture on Mueller Hinton agar plates (BioMérieux, Marcy-l\'Étoile, France) using the MagAttract HMW DNA kit (Qiagen, Hilden, Germany). Using the double-stranded DNA (dsDNA) BR assay kit (Thermo Fisher Scientific, Waltham, MA, USA), 1 ng of input DNA was quantified with a Qubit 2.0 fluorometer (Thermo Fisher Scientific). Library preparation to obtain ready-to-sequence libraries was done with a NexteraXT kit (Illumina, Inc., San Diego, CA, USA). Paired-end sequencing (2 × 300 bp) was performed using a MiSeq system (Illumina, Inc.) and generated 3,174,214 reads from 687,587,445 unassembled nucleotides. Raw reads were *de novo* assembled into a draft genome using SPAdes version 3.9.0 ([@B4]). Contigs were filtered for a minimum coverage of 5 and minimum length of 200 bp, which resulted in 272 contigs with a total of 5,687,772 nucleotides at a coverage of 133-fold.

Antimicrobial resistance genes were identified using the ResFinder tool ([@B5]) from the Center of Genomic Epidemiology (CGE) (<http://www.genomicepidemiology.org>) and included *bla*~VIM-1~, *bla*~ACC-1~, *bla*~SRT-2~, *aadA1*, *aadA16*, *aac(6\')-Ic*, *aac(6\')Ib-cr*, *qnrB6*, *tet*(41), *dfrA27*, *arr-3*, *catA1*, and *sul1*, conferring resistance to β-lactam antibiotics, aminoglycosides, quinolones, tetracyclines, trimethoprim, rifampin, phenicol, and sulfonamides. The PlasmidFinder tool from CGE ([@B6]) identified two plasmids (IncHI2, IncHI2A). The NCBI Prokaryotic Genome Automatic Annotation Pipeline identified 5,674 genes, 5,552 coding sequences, 194 pseudo-genes, 19 rRNA operons (9 complete, 10 partial), and 82 tRNA genes.
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This whole-genome shotgun project has been deposited at DDBJ/ENA/GenBank under the accession number [NPIX00000000](http://www.ncbi.nlm.nih.gov/nuccore/NPIX00000000). The version described in this paper is version NPIX01000000.
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